Lerman C - Search Results

1

Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling.

Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, Pinto A, Hawk L, Niaura R, Epstein LH, Lerman C. Collins BN, et al. Among authors: lerman c. Nicotine Tob Res. 2004 Feb;6(1):27-37. doi: 10.1080/14622200310001656830. Nicotine Tob Res. 2004. PMID: 14982685 Clinical Trial.

2

Attention-Deficit Hyperactivity Disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program.

Lerman C, Audrain J, Tercyak K, Hawk LW Jr, Bush A, Crystal-Mansour S, Rose C, Niaura R, Epstein LH. Lerman C, et al. Nicotine Tob Res. 2001 Nov;3(4):353-9. doi: 10.1080/14622200110072156. Nicotine Tob Res. 2001. PMID: 11694203 Clinical Trial.

3

Mediating mechanisms for the impact of bupropion in smoking cessation treatment.

Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Lerman C, et al. Drug Alcohol Depend. 2002 Jul 1;67(2):219-23. doi: 10.1016/s0376-8716(02)00067-4. Drug Alcohol Depend. 2002. PMID: 12095672 Clinical Trial.

4

Applying genetic approaches to the treatment of nicotine dependence.

Lerman C, Niaura R. Lerman C, et al. Oncogene. 2002 Oct 21;21(48):7412-20. doi: 10.1038/sj.onc.1205801. Oncogene. 2002. PMID: 12379882 Review.

5

Pharmacogenetic investigation of smoking cessation treatment.

Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L. Lerman C, et al. Pharmacogenetics. 2002 Nov;12(8):627-34. doi: 10.1097/00008571-200211000-00007. Pharmacogenetics. 2002. PMID: 12439223 Clinical Trial.

6

Dopamine transporter genotype as a risk factor for obesity in African-American smokers.

Epstein LH, Jaroni JL, Paluch RA, Leddy JJ, Vahue HE, Hawk L, Wileyto EP, Shields PG, Lerman C. Epstein LH, et al. Among authors: lerman c. Obes Res. 2002 Dec;10(12):1232-40. doi: 10.1038/oby.2002.168. Obes Res. 2002. PMID: 12490667 Free article.

7

Individual differences in nicotine intake per cigarette.

Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, Kucharski S, Lerman C. Patterson F, et al. Among authors: lerman c. Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):468-71. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12750245

8

Comparison between two measures of delay discounting in smokers.

Epstein LH, Richards JB, Saad FG, Paluch RA, Roemmich JN, Lerman C. Epstein LH, et al. Among authors: lerman c. Exp Clin Psychopharmacol. 2003 May;11(2):131-8. doi: 10.1037/1064-1297.11.2.131. Exp Clin Psychopharmacol. 2003. PMID: 12755457

9

Genes, smoking, and treatment response.

Kaufmann V, Lerman C. Kaufmann V, et al. Among authors: lerman c. Am J Health Syst Pharm. 2003 Sep 15;60(18):1911. doi: 10.1093/ajhp/60.18.1911. Am J Health Syst Pharm. 2003. PMID: 14521049 No abstract available.

10

Which adolescents are most receptive to tobacco industry marketing? implications for counter-advertising campaigns.

Audrain-McGovern J, Tercyak KP, Shields AE, Bush A, Espinel CF, Lerman C. Audrain-McGovern J, et al. Among authors: lerman c. Health Commun. 2003;15(4):499-513. doi: 10.1207/S15327027HC1504_07. Health Commun. 2003. PMID: 14527869

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

429 results

Search Page